LAWRENCEVILLE, N.J.,
Oct. 29, 2015 /PRNewswire/
-- Celsion Corporation (NASDAQ: CLSN) announced today that the
Company will host a conference call to discuss its third quarter
2015 financial results and provide an update on its development
programs for ThermoDox®, its proprietary heat-activated liposomal
encapsulation of doxorubicin, and two newly acquired technology
platforms, TheraPlas™ and TheraSilence™, in immunotherapy and RNA
delivery at 11:00 a.m. EST on
Thursday, November 5, 2015. To
participate in the call, interested parties may dial 1-877-419-6594
(Toll-Free/North America) or
1-719-325-4755 (International/Toll) and ask for the Celsion
Corporation Third Quarter 2015 Conference Call (Conference Code:
939465) to register ten minutes before the call is scheduled to
begin. The call will also be broadcast live on the internet at
http://www.celsion.com.
The call will be archived for replay on November 5, 2015 and will remain available until
November 19, 2015. The replay
can be accessed at 1-888-203-1112 (Toll-Free/North America) or +1 719-457-0820
(International/Toll) using Conference ID: 939465.
An audio replay of the call will also be available on the
Company's website, http://www.celsion.com, for 30 days after
2:00 p.m. EST Thursday, November 5,
2015.
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on
developing a portfolio of innovative cancer treatments, including
directed chemotherapies, immunotherapies and RNA- or DNA-based
therapies. The Company's lead program is ThermoDox®, a proprietary
heat-activated liposomal encapsulation of doxorubicin, currently in
Phase III development for the treatment of primary liver cancer and
in Phase II development for the treatment of recurrent chest wall
breast cancer. The pipeline also includes GEN-1, a DNA-based
immunotherapy for the localized treatment of ovarian and brain
cancers. Celsion has three platform technologies
for the development of novel nucleic acid-based immunotherapies and
other anti-cancer DNA or RNA therapies, including TheraPlas™ and
TheraSilence™. For more information on Celsion, visit
our website: http://www.celsion.com.
Celsion Investor Contact
Jeffrey W. Church
Senior Vice President and CFO
609-482-2455
jchurch@celsion.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/celsion-corporation-to-hold-third-quarter-2015-financial-results-conference-call-on-thursday-november-5-2015-300168497.html
SOURCE Celsion Corporation